1. Scrip

Coronavirus Update: Pfizer Pledges To Double US Vaccine Output

Plus: Novavax Signs Pact For Equitable Vaccine Access

 
• By Scrip Team

A round-up of the latest developments, including Celltrion’s new antibody cocktail and SK Biosience and Novavax expanding their collaboration.

Bourla Biden Kalamazoo
President Biden listens to Pfizer CEO Albert Bourla speak at the company's manufacturing facility in Kalamazoo, Michigan.

Pfizer expects to double its weekly output from US COVID-19 vaccines manufacturing sites, the company’s CEO Albert Bourla said at an event with President Joe Biden at its plant in Kalamazoo, Michigan. 

President Biden visited the site on 19 February, as his administration looks to accelerate the pace of production and vaccination...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from Scrip

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 
• By Andrew McConaghie

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer

 
• By Andy Smith

The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By Lisa Takagi

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.